Landscape Capital Management L.L.C. Invests $1.72 Million in Sarepta Therapeutics, Inc. $SRPT

Landscape Capital Management L.L.C. acquired a new position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 79,671 shares of the biotechnology company’s stock, valued at approximately $1,715,000. Landscape Capital Management L.L.C. owned 0.08% of Sarepta Therapeutics as of its most recent SEC filing.

A number of other institutional investors also recently made changes to their positions in SRPT. AQR Capital Management LLC boosted its holdings in shares of Sarepta Therapeutics by 214.2% during the first quarter. AQR Capital Management LLC now owns 5,385 shares of the biotechnology company’s stock worth $344,000 after acquiring an additional 3,671 shares during the period. Great Lakes Advisors LLC bought a new stake in shares of Sarepta Therapeutics during the first quarter worth approximately $224,000. Guggenheim Capital LLC boosted its holdings in shares of Sarepta Therapeutics by 33.5% during the second quarter. Guggenheim Capital LLC now owns 45,790 shares of the biotechnology company’s stock worth $783,000 after acquiring an additional 11,497 shares during the period. First Trust Advisors LP boosted its holdings in shares of Sarepta Therapeutics by 59.2% during the second quarter. First Trust Advisors LP now owns 627,561 shares of the biotechnology company’s stock worth $10,731,000 after acquiring an additional 233,391 shares during the period. Finally, California Public Employees Retirement System boosted its holdings in shares of Sarepta Therapeutics by 7.1% during the second quarter. California Public Employees Retirement System now owns 115,340 shares of the biotechnology company’s stock worth $1,972,000 after acquiring an additional 7,665 shares during the period. Institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Trading Up 3.0%

Shares of SRPT stock opened at $15.77 on Tuesday. The company has a current ratio of 4.63, a quick ratio of 2.62 and a debt-to-equity ratio of 0.56. The stock has a market cap of $1.66 billion, a P/E ratio of -16.43, a price-to-earnings-growth ratio of 0.16 and a beta of 0.21. The stock has a 50 day simple moving average of $19.08 and a 200 day simple moving average of $19.73. Sarepta Therapeutics, Inc. has a 1 year low of $10.41 and a 1 year high of $25.32.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $3.16 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.98 by $2.18. The business had revenue of $730.80 million during the quarter, compared to analysts’ expectations of $474.16 million. Sarepta Therapeutics had a positive return on equity of 7.56% and a negative net margin of 2.94%.The firm’s revenue for the quarter was down 1.9% compared to the same quarter last year. During the same period in the previous year, the company posted ($3.42) earnings per share. On average, research analysts predict that Sarepta Therapeutics, Inc. will post 3.99 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on SRPT shares. Deutsche Bank Aktiengesellschaft boosted their price objective on Sarepta Therapeutics from $12.00 to $14.00 and gave the stock a “sell” rating in a report on Thursday, March 26th. Loop Capital set a $25.00 price objective on Sarepta Therapeutics in a report on Tuesday, March 3rd. Mizuho boosted their price target on Sarepta Therapeutics from $26.00 to $31.00 and gave the company an “outperform” rating in a research note on Thursday, March 12th. Wedbush boosted their price target on Sarepta Therapeutics from $29.00 to $35.00 and gave the company an “outperform” rating in a research note on Thursday, March 26th. Finally, Royal Bank Of Canada boosted their price target on Sarepta Therapeutics from $18.00 to $19.00 and gave the company a “sector perform” rating in a research note on Tuesday, April 7th. Eight analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and six have issued a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $24.77.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.